Back to Search Start Over

Impact of Mitral Regurgitation Etiology on Mitral Surgery After Transcatheter Edge-to-Edge Repair

Authors :
Zaid, Syed
Avvedimento, Marisa
Vitanova, Keti
Akansel, Serdar
Bhadra, Oliver
Ascione, Guido
Saha, Shekhar
Noack, Thilo
Tagliari, Ana Paula
Pizano, Alejandro
Donatelle, Marissa
Squiers, John
Goel, Kashish
Leurent, Guillaume
Asgar, Anita
Ruaengsri, Chawannuch
Wang, Lin
Leroux, Lionel
Flagiello, Michele
Algadheeb, Muhanad
Werner, Paul
Ghattas, Angie
Bartorelli, Antonio
Dumonteil, Nicholas
Geirsson, Arnar
van Belle, Eric
Massi, Francesco
Wyler von Ballmoos, Moritz
Goel, Sachin
Reardon, Michael
Bapat, Vinayak
Nazif, Tamim
Kaneko, Tsuyoshi
Modine, Thomas
Denti, Paolo
Tang, Gilbert
Tang, Gilbert H.L.
Houston Methodist Hospital [Houston, TX, USA]
Laboratoire Traitement du Signal et de l'Image (LTSI)
Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)
CHU Pontchaillou [Rennes]
CHU Bordeaux [Bordeaux]
Hospices Civils de Lyon (HCL)
Clinique Pasteur
Clinique Pasteur [Toulouse]
CHU Lille
Mount Sinai Health System
Dr Bhadra has received travel compensation from Edwards Lifesciences. Dr Tagliari has received research support from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Dr Leurent has been a consultant and physician proctor for and has received speaker honoraria from Abbott. Dr Asgar has been a consultant for Medtronic, Abbott, Edwards Lifesciences, and W. L. Gore & Associates
and has received research grants from Abbott. Dr Leroux has been a physician proctor for Medtronic and Abbott
and a consultant for Edwards Lifesciences. Dr Dumonteil has received speaker honoraria and travel reimbursement by Edwards Lifesciences
and has been a physician proctor and consultant for Edwards Lifesciences. Dr Geirsson has been a member of the Medtronic Strategic Surgical Advisory Board. Dr Wyler von Ballmoos has served as a consultant for LivaNova, Medtronic, and Boston Scientific. Dr Reardon has been a consultant for Medtronic, Boston Scientific, Abbott, and W. L. Gore & Associates. Dr Bapat has served as a consultant for Medtronic, Edwards Lifesciences, 4C Medical, and Boston Scientific. Dr Nazif has equity in Venus Medtech
and has received consulting fees or honoraria from Keystone Heart, Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Kaneko has been a speaker for Edwards Lifesciences, Medtronic, Abbott, and Baylis Medical
and has been a consultant for 4C Medical. Dr Modine has been a physician proctor and consultant for Medtronic, Edwards Lifesciences, and Abbott. Dr Denti has received speaker honoraria from Abbott and Edwards Lifesciences
and has been a consultant for InnovHeart. Dr Tang has been a physician proctor for Medtronic
a consultant for Medtronic, Abbott, and NeoChord
and a physician advisory board member for Abbott, Boston Scientific and JenaValve
and has received speaker honoraria from Siemens Healthineers and East End Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Source :
JACC: Cardiovascular Interventions, JACC: Cardiovascular Interventions, 2023, 16 (10), pp.1176-1188. ⟨10.1016/j.jcin.2023.02.029⟩
Publication Year :
2023
Publisher :
Elsevier BV, 2023.

Abstract

International audience; Background: Although >150,000 mitral TEER procedures have been performed worldwide, the impact of MR etiology on MV surgery after TEER remains unknown.Objectives: The authors sought to compare outcomes of mitral valve (MV) surgery after failed transcatheter edge-to-edge repair (TEER) stratified by mitral regurgitation (MR) etiology.Methods: Data from the CUTTING-EDGE registry were retrospectively analyzed. Surgeries were stratified by MR etiology: primary (PMR) and secondary (SMR). MVARC (Mitral Valve Academic Research Consortium) outcomes at 30 days and 1 year were evaluated. Median follow-up was 9.1 months (IQR: 1.1-25.8 months) after surgery.Results: From July 2009 to July 2020, 330 patients underwent MV surgery after TEER, of which 47% had PMR and 53.0% had SMR. Mean age was 73.8 ± 10.1 years, median STS risk at initial TEER was 4.0% (IQR: 2.2%-7.3%). Compared with PMR, SMR had a higher EuroSCORE, more comorbidities, lower LVEF pre-TEER and presurgery (all P < 0.05). SMR patients had more aborted TEER (25.7% vs 16.3%; P = 0.043), more surgery for mitral stenosis after TEER (19.4% vs 9.0%; P = 0.008), and fewer MV repairs (4.0% vs 11.0%; P = 0.019). Thirty-day mortality was numerically higher in SMR (20.4% vs 12.7%; P = 0.072), with an observed-to-expected ratio of 3.6 (95% CI: 1.9-5.3) overall, 2.6 (95% CI: 1.2-4.0) in PMR, and 4.6 (95% CI: 2.6-6.6) in SMR. SMR had significantly higher 1-year mortality (38.3% vs 23.2%; P = 0.019). On Kaplan-Meier analysis, the actuarial estimates of cumulative survival were significantly lower in SMR at 1 and 3 years.Conclusions: The risk of MV surgery after TEER is nontrivial, with higher mortality after surgery, especially in SMR patients. These findings provide valuable data for further research to improve these outcomes.

Details

ISSN :
19368798
Volume :
16
Database :
OpenAIRE
Journal :
JACC: Cardiovascular Interventions
Accession number :
edsair.doi.dedup.....f7bd943456d5d43c6aac43f3b9c3e8a9
Full Text :
https://doi.org/10.1016/j.jcin.2023.02.029